Insights from FD/MAS Mouse Model – Dr. Biagio Palmisano

Dr. Palmisano presents research on fibrous dysplasia (FD) using a mouse model with a GS Alpha r21c mutation. The mouse model mirrors the postnatal development of FD seen in humans, progressing from monostotic to polyostotic disease. Histopathological features of FD, including fibrous tissue deposition and osteoclast presence, are observed.
The presentation explores therapeutic strategies, focusing on a novel approach combining an anti-cant (denosumab analog) and zoledronate to prevent disease rebound post-treatment discontinuation. Results show promise in preventing or delaying FD progression. The study also examines behavioral signs of pain in FD mice using burrowing, nesting, and tail tests. The tests indicate reduced burrowing and nesting abilities and delayed nociceptive responses in FD mice, suggesting the development of bone pain.
In conclusion, the presentation highlights the potential efficacy of the combined anti-cant and zoledronate treatment in ameliorating bone pain behavior in FD mice, offering insights into the clinical expression of the disease.
The FD/MAS Alliance Community Conference combined patient-centered science and real-world strategies for patients and families living with fibrous dysplasia, McCune-Albright syndrome (FD/MAS).
The FD/MAS Alliance (formerly Fibrous Dysplasia Foundation) is a community-driven 501c3 nonprofit that fosters the development of evidence-based treatments for Fibrous Dysplasia and McCune-Albright syndrome (FD/MAS). We advance research, provide education and channel the voices of individuals and caregivers with FD/MAS. To support our work visit www.fdmasalliance.org/donate